Breakthrough Drugs for GI Disease Management

Thetis Pharmaceuticals LLC is a biopharmaceutical company that is developing novel drugs for treatment of inflammation-related gastrointestinal (GI) diseases with high unmet medical needs. Our drug candidates deliver bioactive lipids that have been shown to have clinical efficacy in Phase II randomized control trials.

Using our HEALER™ platform technology, we create novel derivatives of bioactive lipids that have improved pharmaceutical properties and strong intellectual property protection. Our lead drug candidate, TP-252, is targeted at managing polyp progression in young patients with familial adenomatous polyposis (FAP), a rare genetic disease. Thetis has received orphan drug designation for TP-252 for treatment of FAP from the FDA Office of Orphan Products Development.

Beyond TP-252, we are using our HEALER technology to develop a new class of drugs that deliver specialized proresolving mediators (SPMs) for treatment of GI diseases. Experimental models have established that SPMs offer prospects for preventing and treating non-resolving inflammation associated with inflammatory bowel disease.

Learn more about our HEALER platform. »»

Upcoming Events

  • World Orphan Drug Congress: Presenting FAP Program
    (3:30 pm ET, April 20)
  • Digestive Disease Week:
    • Presenting TP-252 Pre-clinical Efficacy Study Results               (3pm CT, May 8, Room S102D)
    • Exhibition Booth #2004 (May 7-9)
  • BIO International Convention: Partnering track participant
    (June 19-22)